Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, DubaiAccesswire · 3 days ago
Contrasting Hypermarcas (OTCMKTS:HYPMY) and Ensysce Biosciences (NASDAQ:ENSC)Defense World · Sep 29, 2026
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRAAccesswire · Sep 24, 2026
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug RegulationAccesswire · Sep 15, 2026
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic DrugsAccesswire · Sep 14, 2026
Ensysce Biosciences Announces Upcoming Conference and Industry Event ParticipationAccesswire · Sep 2, 2026Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.20 | -$0.20 | Beat |
| May 15, 2026 | -$0.73 | -$0.52 | Beat |
| Mar 30, 2026 | -$1.26 | -$0.75 | Beat |
| Nov 14, 2025 | -$0.85 | -$1.29 | Miss |
| Aug 13, 2025 | -$1.02 | -$0.79 | Beat |
| May 13, 2025 | -$3.02 | -$1.39 | Beat |